NASDAQ:ATYR aTyr Pharma Q1 2025 Earnings Report $0.55 0.00 (-0.18%) As of 09:50 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast aTyr Pharma EPS ResultsActual EPS-$0.17Consensus EPS -$0.19Beat/MissBeat by +$0.02One Year Ago EPSN/AaTyr Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AaTyr Pharma Announcement DetailsQuarterQ1 2025Date5/7/2025TimeBefore Market OpensConference Call DateTuesday, May 6, 2025Conference Call Time6:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) aTyr Pharma Earnings HeadlinesQ3 Earnings Estimate for aTyr Pharma Issued By HC WainwrightAugust 14 at 1:43 AM | americanbankingnews.comaTyr Pharma Inc 471AAugust 12 at 12:10 AM | morningstar.comMHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.August 14 at 1:00 AM | Stansberry Research (Ad)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Embecta Corporation (EMBC) and aTyr Pharma (ATYR)August 12 at 9:08 AM | theglobeandmail.comATyr Pharma to Cut 60% of Staff, Bring in New CFO in Restructuring PushAugust 8, 2026 | marketwatch.comAtyr Pharma: Q2 Earnings SnapshotAugust 8, 2026 | sfgate.comSee More aTyr Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like aTyr Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on aTyr Pharma and other key companies, straight to your email. Email Address About aTyr PharmaaTyr Pharma (NASDAQ:ATYR) is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors. The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling. Its lead program, ATYR1923, is being investigated for the treatment of pulmonary sarcoidosis, and additional pipeline candidates are advancing in preclinical and early clinical studies for oncology and neuromuscular disorders. aTyr’s platform allows for the rapid screening of protein interactions and the engineering of modulators with potential applications across multiple therapeutic areas. Founded in 2005, aTyr Pharma completed its initial public offering in 2015 and has since entered into strategic collaborations to accelerate the development and potential commercialization of its product candidates. The company’s research and development activities span North America and Europe, and its leadership team brings together expertise in protein therapeutics, immunology, and clinical development. aTyr continues to leverage its platform to address unmet medical needs and to expand its pipeline through internal discovery and external partnerships.View aTyr Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?SpaceX’s First Earnings Report Only Made Wall Street More DividedFranco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care?Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not DemandLumentum Just Delivered the AI Growth Investors WantedCoreWeave's $129 Billion AI Backlog Changes the Bull Case Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
